Ocrevus (ocrelizumab)

P3, N=171, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P=N/A, N=111, Not yet recruiting, Region Stockholm

P3, N=444, Not yet recruiting, Amgen

P2, N=120, Completed, Peking University People's Hospital; Department of Neurology, Peking University People’s Hospital | Not yet recruiting --> Completed

P2, N=124, Completed, Peking University People's Hospital; Department of Neurology, Peking University People’s Hospital | Not yet recruiting --> Completed

P2, N=132, Completed, Peking University People's Hospital; Department of Neurology, Peking University People’s Hospital | Not yet recruiting --> Completed

P1, N=34, Not yet recruiting, Indapta Therapeutics, INC.

P3, N=500, Not yet recruiting, Hoffmann-La Roche

P=N/A, N=100, Not yet recruiting, Novartis Pharmaceuticals

P=N/A, N=18, Completed, University of South Florida | Active, not recruiting --> Completed

P=N/A, N=14, Completed, Providence Health & Services | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Nov 2023

P=N/A, N=732, Completed, State University of New York at Buffalo | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024

P2, N=23, Active, not recruiting, Hoffmann-La Roche | N=36 --> 23

P3, N=1000, Recruiting, Hoffmann-La Roche | Trial completion date: Nov 2030 --> Jan 2028 | Trial primary completion date: Dec 2027 --> Jan 2025

P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial primary completion date: Apr 2030 --> Jul 2027

P=N/A, N=168, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=240 --> 168

Therapy with ocrelizumab, teriflunomide or dimethyl fumarate reduced EBV-specific, but not CMV-specific MHC-I-restricted TRB sequence matches. Together, this data suggests that the aberrant MHC-I-restricted T-cell response directed against EBV is specific to MS with regard to NMO, MOGAD and Susac's Syndrome and that it is specifically modified by MS treatments interfering with EBV host cells or activated lymphocytes.

P4, N=10, Completed, Johns Hopkins University | Active, not recruiting --> Completed

P4, N=20, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting

P4, N=5, Not yet recruiting, University of California, San Francisco

Disease-modifying therapies (DMTs) impact the cellular immune response to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with multiple sclerosis (pwMS)...Therefore, the measurement of IL-2 and IL-5 levels could complement traditional IFN-γ assays to more comprehensively characterize the cellular responses to SARS-CoV-2 vaccines. Our results provide a comprehensive cytokine profile for pwMS receiving different DMTs and offer valuable insights for designing vaccination strategies in this patient population.

P=N/A, N=35, Completed, University of Michigan | Recruiting --> Completed

P3, N=512, Recruiting, Celltrion | Not yet recruiting --> Recruiting

P3, N=72, Active, not recruiting, Centre Hospitalier Universitaire de Nice | Recruiting --> Active, not recruiting

P3, N=600, Active, not recruiting, Rigshospitalet, Denmark | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> May 2028 | Trial primary completion date: Dec 2025 --> May 2026

P3, N=1300, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2029

P4, N=800, Active, not recruiting, The Cleveland Clinic | Recruiting --> Active, not recruiting

Historically, B and T cell (B-T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and organ transplantation benefit from targeted BCD with anti-CD20 monoclonal antibodies such as rituximab, ocrelizumab or ofatumumab...In the treatment of cancer, chimeric antigen receptor (CAR) T cell therapy and T cell engagers (TCE) that recruit T cells to induce B cell cytotoxicity have delivered promising results for anti-CD19 CAR T cell therapies, the CD19 TCE blinatumomab and CD20 TCE such as mosunetuzumab, glofitamab or epcoritamab. Limited evidence suggests that anti-CD19 CAR T cell therapy may be effective in managing refractory AID whereas we await evaluation of TCE for use in non-oncological indications. Therefore, here, we discuss the potential mechanistic advantages of novel therapies that rely on T cells as effector cells to disrupt B-T cell collaboration toward overcoming rituximab-resistant AID.

P1, N=134, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Jan 2023 --> Jun 2025

P=N/A, N=732, Active, not recruiting, State University of New York at Buffalo | Trial primary completion date: Mar 2024 --> Jun 2024

P=N/A, N=732, Active, not recruiting, State University of New York at Buffalo | Trial primary completion date: Mar 2024 --> Nov 2024

P3, N=1500, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2025 --> Sep 2025

P4, N=179, Active, not recruiting, Genentech, Inc. | Trial primary completion date: Dec 2022 --> Dec 2025

P3, N=236, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Mar 2023 --> Apr 2025

P=N/A, N=14, Active, not recruiting, Providence Health & Services | Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2024

P4, N=44, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P3, N=769, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2029 --> Mar 2029 | Trial primary completion date: Nov 2025 --> Apr 2025

P3, N=19, Completed, Providence Health & Services | Active, not recruiting --> Completed | N=52 --> 19

P2, N=220, Completed, Genentech, Inc. | Active, not recruiting --> Completed

P4, N=179, Active, not recruiting, Genentech, Inc. | Trial completion date: Aug 2025 --> Dec 2025

P=N/A, N=60, Recruiting, Kessler Foundation | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P4, N=20, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting